NasdaqGS - Nasdaq Real Time Price • USD
Cytokinetics, Incorporated (CYTK)
As of 10:10 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 15 |
| Avg. Estimate | -1.16 | -1.14 | -4.69 | -4.2 |
| Low Estimate | -1.38 | -1.42 | -5.43 | -5.97 |
| High Estimate | -1.02 | -0.95 | -4.28 | -2.94 |
| Year Ago EPS | -1.34 | -1.35 | -5.45 | -4.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 12 |
| Avg. Estimate | 950k | 870k | 9.84M | 83M |
| Low Estimate | -- | -- | 800k | 5M |
| High Estimate | 2M | 1.32M | 53.36M | 225.9M |
| Year Ago Sales | 5.8M | 378k | 7.53M | 9.84M |
| Sales Growth (year/est) | -83.60% | 130.20% | 30.70% | 743.50% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.15 | -0.74 | -0.97 | -1.14 |
| EPS Actual | -1.34 | -1.35 | -1.38 | -1.33 |
| Difference | -0.19 | -0.61 | -0.41 | -0.19 |
| Surprise % | -16.50% | -82.40% | -42.30% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.16 | -1.14 | -4.69 | -4.2 |
| 7 Days Ago | -1.18 | -1.13 | -4.69 | -4.13 |
| 30 Days Ago | -1.12 | -1.08 | -4.45 | -3.29 |
| 60 Days Ago | -1.12 | -1.08 | -4.45 | -3.28 |
| 90 Days Ago | -1.02 | -1.06 | -4.53 | -3.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 6 | 5 | 4 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CYTK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.40% | -- | -- | 8.00% |
| Next Qtr. | 15.60% | -- | -- | 12.40% |
| Current Year | 13.90% | -- | -- | 5.60% |
| Next Year | 10.40% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
| Reiterates | Needham: Buy to Buy | 5/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/9/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 5/9/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/9/2024 |
Related Tickers
BBIO BridgeBio Pharma, Inc.
29.76
-1.10%
CLRB Cellectar Biosciences, Inc.
3.2500
-1.52%
APLS Apellis Pharmaceuticals, Inc.
41.27
-0.10%
ASND Ascendis Pharma A/S
121.77
+0.53%
JANX Janux Therapeutics, Inc.
47.56
+0.98%
CTMX CytomX Therapeutics, Inc.
1.9150
+1.32%
MDGL Madrigal Pharmaceuticals, Inc.
226.27
+2.82%
BHVN Biohaven Ltd.
39.11
+4.64%
IONS Ionis Pharmaceuticals, Inc.
37.26
-0.15%
FULC Fulcrum Therapeutics, Inc.
7.97
+5.56%